Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.0552W HIGH $19.11
Volume
1.94 M
Value Traded
23.35 M
Short % Float
24.54%
+7.94%Week
-20%1 Month
-76.19%3 Month
-76.58%6 Month
+39.18%5 Year
-96.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
293.12 M
EPS (TTM)
-3.56
P/E Ratio
-
Ent. Value
112.65 M
Total Shares
86.24 M
Float Shares
80.71 M
Insiders
6.38%
Institutions
113.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
EYPT Catalyst Timeline
Dated clinical, regulatory and corporate events for EyePoint, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for EyePoint, Inc.
827Total events
7Upcoming
194Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Topline ReadoutDURAVYUClinical Data
Topline data from LUGANO announced
wet age-related macular degenerationsource ↗
▼Primary Endpoint MissedDURAVYUClinical Data
LUGANO primary endpoint not achieved in full dataset
wet age-related macular degenerationsource ↗
▲Secondary Endpoint DataDURAVYUClinical Data
LUGANO key secondary endpoints achieved
wet age-related macular degenerationsource ↗
▲Enrollment CompleteDURAVYUTrial
Pivotal Phase 3 DME trials COMO and CAPRI completed enrollment with over 480 patients
DMEsource ↗
◆Topline ReadoutDURAVYUClinical Data
Topline data from LUGANO pivotal Phase 3 wet AMD trial expected in August 2026
wet AMDsource ↗
▲Enrollment CompleteDURAVYUTrial
Enrollment completed in both Phase 3 trials COMO and CAPRI for DURAVYU in DME
diabetic macular edemasource ↗
◆Enrollment CompleteDURAVYUTrial
Full enrollment expected in CAPRI trial in DME in Q3 2026
diabetic macular edemasource ↗
◆Topline ReadoutDURAVYUClinical Data
Topline data for LUCIA trial
wet age-related macular degenerationsource ↗
●Oral PresentationDURAVYUPresentation
Multiple oral presentations at ASRS Annual Meeting supporting DURAVYU profile
wet AMD and DMEsource ↗
●Management ChangeCorporate
Tarek S. Hassan, M.D. appointed as Chief Strategic Science Officer
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat
◆Topline ReadoutDURAVYUClinical Data
Topline data for Phase 3 wet AMD trials expected beginning in mid-2026
wet age-related macular degenerationsource ↗
▲DSMB ReviewDURAVYUTrial
Third consecutive positive DSMC recommendation for Phase 3 wet AMD trials
wet age-related macular degenerationsource ↗
▲Enrollment MilestoneDURAVYUTrial
All active patients in treatment arm reached second DURAVYU dosing visit (Week 32)
wet age-related macular degenerationsource ↗
▲Oral PresentationDURAVYUPresentation
Data presented at ARVO 2026 from DAVIO 2 trial in wet AMD
wet age-related macular degenerationsource ↗
▲Preclinical PoCDURAVYUPreclinical
Preclinical data presented at ARVO 2026 demonstrating inhibition of IL-6 signaling by vorolanib
retinal diseasessource ↗
▲DSMB ReviewDURAVYUTrial
Positive DSMC meeting recommended continuation of LUGANO and LUCIA trials
wet AMDsource ↗
◆Topline ReadoutDURAVYUClinical Data
Topline data for DURAVYU in wet AMD anticipated beginning in mid-2026
wet age-related macular degenerationsource ↗
◆Quarterly UpdateCorporate
Fourth Quarter and Full-Year 2025 Financial Results Conference Call
▲First Patient DosedDURAVYUTrial
First patient dosed in Phase 3 CAPRI trial for DURAVYU in DME
Diabetic Macular Edema (DME)source ↗
▲DSMB ReviewDURAVYUTrial
DSMC completed second scheduled review of Phase 3 program, recommended continuation
Wet Age-Related Macular Degeneration (Wet AMD)source ↗
▲Safety Data UpdateDURAVYUClinical Data
Interim masked safety data through September 29, 2025, consistent with favorable safety
Wet Age-Related Macular Degeneration (Wet AMD)source ↗
▲Manufacturing MilestoneDURAVYUCMC / Inspection
Completed manufacturing of registration batches for DURAVYU at commercial facility
●Preclinical PoCDURAVYUPreclinical
Preclinical data demonstrated DURAVYU reduces IL-6 activity by >50%
Wet AMD and DMEsource ↗
▲First Patient DosedDURAVYUTrial
First patient dosed in Phase 3 CAPRI trial of DURAVYU for DME
diabetic macular edemasource ↗
◆Oral PresentationPresentation
EyePoint to present at Guggenheim Emerging Outlook: Biotech Summit 2026
▲Patent GrantedDURAVYUIP / Competition
U.S. patent issued for DURAVYU insert formulation, extending coverage into 2043
●Oral PresentationDURAVYUPresentation
DAVIO 2 and VERONA trial data presented at 49th Annual Macula Society Meeting
Wet AMD and DMEsource ↗
◆Oral PresentationPresentation
EyePoint to present at 44th Annual J.P. Morgan Healthcare Conference
▲First Patient DosedDURAVYUTrial
First patient dosing in pivotal Phase 3 clinical trials in DME expected in Q1 2026
diabetic macular edemasource ↗
●Oral PresentationDURAVYUPresentation
Clinical trial update and post hoc analysis of DAVIO 2 presented at Hawaiian Eye and Retina 2026
Retinal exudative diseasessource ↗
▲Trial InitiationDURAVYUTrial
Initiation of Phase 3 pivotal trials for DME
diabetic macular edema (DME)source ↗
●Quarterly UpdateCorporate
Cash and investments approximately $300 million at December 31, 2025
▲DSMB ReviewDURAVYUTrial
DSMC recommends continuation of LUGANO trial without protocol modifications
wet age-related macular degenerationsource ↗
▲Enrollment CompleteDURAVYUTrial
Phase 3 LUGANO trial fully enrolled
wet age-related macular degeneration (wet AMD)source ↗
▲Trial InitiationDURAVYUTrial
Initiation of pivotal Phase 3 DME program (CAPRI trial)
diabetic macular edema (DME)source ↗
▲Preclinical PoCDURAVYUPreclinical
Preclinical data demonstrating DURAVYU's multi-target MOA inhibiting VEGF and IL-6
wet AMD and DMEsource ↗
Past FDA Catalysts and PDUFA Decisions
How EYPT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-24 | EYP-1901 (Vorolanib Intravitreal Insert) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$54M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.2x
rNPV / MCap
Top 44%
Micro Cap(rank 291 of 660)
Percentile Rank
EyePoint, Inc. faces pipeline headwinds (38/100), with $478M risk-adjusted pipeline value, led by EYP-1901 in Nonproliferative Diabetic Retinopathy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EYP-1901 Small moleculeNCT07449923 | Diabetic Macular Edema | Phase 3 | ACTIVE NOT_RECRUITING | 507 | Oct 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every EYPT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DURAVYU | wet AMD | Phase 3 | 2026-08-17 | 42% reduction in treatment burden achieving superiority versus on-label aflibercept (nominal p-value of <0.0001); 76% of DURAVYU patients were supplement-free up to Week 32; 54% of DURAVYU patients were supplement-free and 79% received 0 or 1 supplement up to Week 56; non-inferiority to supplement-free aflibercept (nominal p-value = 0.0035)Read More | EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMDRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zaderej Karen L.Director | Buy | 10,600 49,100 held | $4.93 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EYPT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| COMMODORE CAPITAL LP | 3.9 % (85.7 %) | 65.78 M | 4.60 M | 62.83% ( 1.77 M) |
EYPT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EYPT ranks across every disease it competes in
Competitive Position is a premium feature
See how EYPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEYPT News
EYPT▼ -5.7%on this news
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. has granted non-statutory stock options to a new employee as an inducement award, complying with NASDAQ Listing Rule 5635(c)(4). The options cover 3,000 shares, with a ten-year term and a vesting schedule over four years. The company is also progressing its lead product candidate, DURAVYU, in Phase 3 trials for wet AMD and DME.
Read more →EYPTEyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
EyePoint, Inc. announced its participation in several upcoming investor conferences and The Retina Society's 59th Annual Scientific Meeting. The company will present findings related to its lead product candidate, EYP-1901, at the scientific meeting. EyePoint's DURAVYU is currently under evaluation in Phase 3 trials for retinal diseases, although FDA approval is not guaranteed.
Read more →EYPT▼ -67%on this news
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
EyePoint announced topline results from the LUGANO trial, the first pivotal Phase 3 study for DURAVYU in wet AMD. While the primary endpoint was not achieved due to confounding factors, key secondary endpoints showed significant improvements, including a 42% reduction in treatment burden and a favorable safety profile. The company anticipates filing for FDA approval in the first half of 2027, pending results from the second trial, LUCIA.
Read more →EYPTEyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. reported its second quarter 2026 financial results, highlighting pivotal Phase 3 trial data expected for its lead product DURAVYU in treating wet AMD and DME. The company has completed enrollment for its DME trials and maintains a strong cash position to fund operations through Q4 2027. Despite a significant net loss and decreased revenue, the outlook remains positive with upcoming data readouts.
Read more →EYPT▲ +7.9%on this news
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
EyePoint, Inc. has successfully completed enrollment in its pivotal Phase 3 trials, COMO and CAPRI, for DURAVYU, a treatment for diabetic macular edema (DME). Over 480 participants were enrolled in just five months, ahead of schedule. Topline data is expected in Q4 2027, with the trials assessing DURAVYU's safety and efficacy against aflibercept. The trials aim to address the treatment burden faced by DME patients.
Read more →EYPTEyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
EyePoint, Inc. has appointed Dr. Tarek S. Hassan as the Chief Strategic Science Officer. Dr. Hassan, a renowned retina specialist, will guide the company's portfolio, particularly the DURAVYU program, which is undergoing Phase 3 trials for wet age-related macular degeneration. His extensive experience is expected to enhance strategic decision-making and growth opportunities for EyePoint.
Read more →EYPTEyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. announced its participation in several upcoming investor conferences, which will feature fireside chats hosted by Stifel, Jefferies, and Goldman Sachs. The company aims to enhance visibility around its innovations and developments, particularly centered on its lead product candidate, DURAVYU, which is undergoing Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. Despite promising data, the FDA approval timeline for DURAVYU is still uncertain, highlighting potential risks for the company.
Read more →EYPTEyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
EyePoint, Inc. has announced a positive recommendation from the Data Safety Monitoring Committee for its Phase 3 trials of DURAVYU for wet AMD. This marks the third consecutive favorable review, suggesting a consistent safety profile ahead of the anticipated mid-2026 topline data release. With all active patients having reached the second dose visit and over 35% receiving a third dose, the company is optimistic about DURAVYU's potential impact on retinal disease treatment.
Read more →EYPTEyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU , Building Confidence Ahead of Mid-2026 Topline Data
EyePoint, Inc. has received a third successive positive recommendation from the independent Data Safety Monitoring Committee for its Phase 3 trials of DURAVYU, aimed at treating wet age-related macular degeneration (AMD). Preliminary safety data from these trials indicate a continued favorable profile consistent with prior studies. All active patients have reached their second dosing visit, with over 35% having received a third dose. Topline data from the trials is anticipated in mid-2026, which could position DURAVYU as a groundbreaking therapy in this therapeutic area.
Read more →EYPTEyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. reported its financial results for Q1 2026, revealing a significant decrease in net revenue while maintaining a robust cash position of $223 million. The company is advancing key Phase 3 trials for its primary product candidate, DURAVYU, in treating wet AMD and diabetic macular edema. Despite increased operating expenses and a growing net loss, the company is optimistic about its upcoming clinical data readouts starting in mid-2026. A conference call was scheduled to discuss these developments further.
Read more →EYPTEyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
EyePoint, Inc. will host a conference call on May 6, 2026, to report its first quarter financial results and discuss recent developments. The company is focused on innovative treatments for retinal diseases, particularly its lead product candidate, DURAVYU, which is under evaluation in Phase 3 trials. Topline data for wet AMD is expected in mid-2026.
Read more →EYPTEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 16, 2026
EyePoint, Inc. announced the granting of non-statutory stock options to fourteen new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). The options, totaling 362,500 shares, have an exercise price of $14.63 and will vest over four years. The company is also advancing its lead product candidate, DURAVYU, in Phase 3 trials for retinal diseases.
Read more →EYPTLegal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and
EyePoint Pharmaceuticals is focusing on its investigational product DURAVYU for retinal diseases, particularly wet AMD and DME. They assert that DURAVYU is well-positioned in the market, was conditionally accepted by the FDA, and is supported by comprehensive clinical data. However, the path to regulatory approval remains uncertain, with significant risks including potential financial constraints and clinical trial outcomes. The company is aiming for key milestones in its Phase 3 clinical trials, which are essential for commercialization.
Read more →EYPTEyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. reported its financial results for Q4 and full-year 2025, highlighting significant developments in its DURAVYU programs. The company is on track for pivotal Phase 3 trial data readouts in mid-2026 for wet AMD and has initiated trials for diabetic macular edema. Despite a substantial net loss and decreased revenues, EyePoint maintains a strong cash position and has appointed a new Chief Commercial Officer to lead its launch strategy.
Read more →About EyePoint, Inc.
Headquarters480 PLEASANT STREET, WATERTOWN, MA, 02472
BIOPHARMAWATCH ELITE PLUS
Trade the next EYPT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime